Tokyo, Japan and Cambridge, UK, 13 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) provides an update on operational activities and reports its consolidated results for the fourth quarter and 12 months ended 31 December 2025. The full report can be viewed here . Christopher Cargill, President and CEO of Nxera Pharma, commented : “2025 was a year of disciplined execution and strategic progress for Nxera, as we continued to build a more focused, resilient and scalable

Moderna reported better-than-expected fourth quarter sales and affirmed revenue growth estimates for 2026 despite soft demand for its COVID-19 vaccine and recent, high-profile pushback from the Food and Drug Administration.The biotechnology company said Friday it recorded revenue of $678 million over the final three months of last year and $1.9 billion for all of 2025, figures that came at the higher end of a projected forecast from November. U.S. sales more than halved between the third and fou

FRIDAY, Feb. 13, 2026 -- Actigraphy measures of sleep phase variability and daily activity amplitude are associated with relapse of depression , according to a study published online Feb. 11 in JAMA Psychiatry . Andre C. Tonon, M.D., Ph.D., from McMaster University in Hamilton, Ontario, Canada, and colleagues examined whether actigraphy-derived parameters, measured over one to two years, are associated with relapse in an observational cohort study. A referred sample of 102 patients from outpatie

RESEARCH TRIANGLE PARK, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc . (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that it has entered into a securities purchase agreement for a private placement (the “private placement”) of 7,374,632 shares of its Series B Non-Voting Convertible Preferred Stock at a

Submission marks key step in study of mesenchymal stem cell therapy to treat symptomatic cartilage defects in patients with knee osteoarthritis CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today that it has filed an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) to support the initiation of a Phase I

Shares in Vertex Pharmaceuticals jumped 6% Friday morning after the biotechnology company reported earnings that included stronger sales for its cell-based therapy Casgevy.Vertex notched $12 billion in 2025, with about $3.2 billion coming in during the fourth quarter. Overall, sales were up 9% year-over-year.Casgevy, Vertex and CRISPR Therapeutics therapy for sickle cell disease and beta thalassemia, brought in $54 million in the fourth quarter and $116 million last year, outstripping Wall Stree

FRIDAY, Feb. 13, 2026 -- Adult obesity is a risk factor for infection-related hospitalizations and mortality, with about 10 percent of infection-related deaths due to obesity in 2023, according to a study published online Feb. 9 in The Lancet . Solja T. Nyberg, Ph.D., from the University of Helsinki in Finland, and colleagues used pooled data from two Finnish cohort studies and repeated analyses in an independent population from the U.K. Biobank to examine the association between adult obesity

FRIDAY, Feb. 13, 2026 -- Menopause is not associated with chronic rhinosinusitis (CRS), while estrogen-containing contraceptive use is associated with reduced odds of CRS without nasal polyps (CRSsNP), according to a study published in the February issue of Otolaryngology-Head and Neck Surgery . Abraham Ahn, from the University of Illinois Chicago, and colleagues conducted a cross-sectional analysis using a national dataset of adults from the All of Us Research Program to examine the association

London, UK - February 19, 2026 BETHESDA, Md. , Feb. 13, 2026 /PRNewswire/ -- Precision Biologics, Inc. CEO Philip M. Arlen, MD gives a Keynote presentation describing in vitro and in vivo efficacy of its novel tumor-specific antibody-drug-conjugate PB-223 ADC (PB-vcMMAE-5). Recent tumor killing data showing specific non-toxic anti-tumor activity in several human cancer types expressing truncated core 2 O-glycans will be reported in "PB-223, A Novel Antibody Drug Conjugate Targeting Truncat

HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin , a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following upcoming investor conferences: Oppenheimer 36th Annual Healthcare Life Sciences Conference Date: Thursday, February 26, 2026 T